| Jul 26 |
June PCE inflation print, auto earnings: Morning Brief
|
| Jul 26 |
Viking’s new dual GLP-1R/GIPR agonist expected to start Phase III trials soon
|
| Jul 26 |
Eli Lilly loses $120B in value over Viking's GLP-1 progress
|
| Jul 25 |
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
|
| Jul 25 |
Why Viking’s Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk Stocks
|
| Jul 25 |
Viking Therapeutics weight-loss drug moves to Phase 3 trial
|
| Jul 25 |
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
|
| Jul 25 |
Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
|
| Jul 25 |
Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk
|
| Jul 25 |
Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill
|
